ReViral Ltd.: Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

Proposed acquisition strengthens Pfizer's capabilities in infectious disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory

Related Keywords

,Alan Musso ,Annaliesa Anderson ,Deborah Cockerill Jasmin Shearan ,Stuart Cockerill ,Albert Bourla ,Alexc Sapir ,Ken Powell ,Linkedin ,Data Safety Monitoring Committee ,Drug Administration ,Centerview Partners ,Sciad Communications Ltd ,Exchange Commission ,Pfizer ,Youtube ,Pfizer Inc ,Clifford Chance ,Goodwin Procter ,Reviral Ltd ,Chief Executive Officer ,Senior Vice President ,Chief Scientific Officer ,Bacterial Vaccines ,Fast Track ,Safety Monitoring Committee ,Bofa Securities ,Breakthroughs That Change Patient Lives ,Pfizer News ,Annual Report ,Looking Information ,Factors That May Affect Future ,Viral Contacts ,Cockerill Jasmin Shearan Darya Shulakova ,Communications Ltd ,Reviral ,Cquire ,Espiratory ,Syncytial ,Virus ,Herapeutic ,Candidates ,